BioScience Fact Sheet

Baxter's BioScience business continues a 60-year legacy of providing life-saving and life-sustaining specialty therapies. The products and therapies Baxter's BioScience organization produces are varied, but they share the common connection of improving the lives of patients with rare conditions, chronic diseases or limited treatment options.

BioScience Expertise

Baxter continues to advance innovation in medical science by developing and improving products and therapies for patients across a range of critical care disciplines.

  • Antibody therapy - Baxter is a leading provider of immunoglobulin therapies for people living with immunodeficiencies and multifocal motor neuropathy around the world.

  • Critical care therapy - Albumin is a plasma-volume expander used to treat burns and maintain adequate fluid volume in critically ill patients. Baxter is the only company to offer albumin in both flexible plastic bags and in glass containers. The flexible container weighs less, eliminates the risk of breaking and streamlines infusion set up, enabling its use in diverse conditions.

  • Pulmonology therapy - For people who have reduced levels of a blood protein, alpha 1-proteinase inhibitor, Baxter provides therapies that raise these blood-protein levels. Without these, the condition can result in early-onset emphysema and premature death.

  • Regenerative medicine and biosurgery - Baxter offers biological products and delivery devices used for hemostasis, tissue sealing, adhesion reduction, hard tissue regeneration, as well as soft tissue repair and microsurgery products.

  • Hemophilia therapy - A leading innovator in hemophilia management, Baxter develops recombinant and plasma-based therapies for people with hemophilia.

  • Vaccines - Baxter provides vaccines for seasonal and pandemic influenza, as well as meningitis C, and tick-borne encephalitis. Baxter's Vero cell technology, used in flu vaccine production, offers potential advantages over traditional egg-based vaccine production methods.

Research & Development

Baxter's BioScience business is supported by a robust research pipeline. The desire to improve the lives of patients drives the organization's research and development priorities, including the development of advanced hemophilia therapies; the investigation of treatments for other bleeding disorders; uses for current therapies in the treatment of Alzheimer's disease; novel treatments for vascular disease and tissue regeneration; and discovery and development of biosimilar products.

BioScience Facts

> BioScience is one of two major business units at Baxter
> 2012 BioScience sales reached $6.2 billion
> The BioScience business operates nine manufacturing facilities in seven countries

Legacy of Innovation

Baxter invests in innovation to continually improve patient outcomes.

> First system for separating plasma from whole blood and storing [1941]
> First commercially produced factor VIII concentrate to treat hemophilia [1968]
> Creation of modern wound sealing, transforming surgical procedures [1973]
> Baxter introduced an anti-inhibitor coagulant complex, the first product for people with hemophilia who have antibodies against factor VIII [1977]
> First heat-treated factor VIII, concentrate significantly reducing risk of contamination by blood-borne viruses [1983]
> Introduced the first genetically engineered recombinant factor VIII [1992]
> Introduced the first full-length recombinant factor VIII treatment that is processed without blood-based additives [2003]
> First albumin in a flexible, plastic container [2005]
> First company to offer alternative to egg-based vaccines, using vero cell technology [2009]